Antibodies directed against the alpha chain of IL7 receptor—their use for the preparation of drug candidates
US9447182B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Oct 4, 2012 |
| Grant date | Sep 20, 2016 |
| Priority date | — |
| Expiry date | Oct 24, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention concerns antibodies directed against CD127, I.e. the alpha chain of the receptor for interleukin7 (IL-7), especially the receptor for human IL-7 expressed on human cells (designated human IL-7R alpha or IL-7Ra) or the TSLP receptor. The antibodies of the invention have cytotoxic activity against CD127 positive cells. The invention also relates to the use of these antibodies in order to deplete subpopulations of T lymphocytes as a result of cytotoxic action of the antibodies, through ADCC and optionally through CDC. Accordingly the invention concerns the use of the antibodies in the treatment of transplant rejection, autoimmune diseases, allergic diseases, lymphoma or cancer when these pathologies are associated with CD127 positive cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.